Actelion's high potential in hypertension has United Therapeutics on ropes
This article was originally published in Scrip
Executive Summary
Actelion's impressive data from a Phase III study of pulmonary arterial hypertension (PAH) drug selexipag have shown that the drug can decrease patients' risk of mortality/morbidity events, squeezing competitor United Therapeutics' products into a corner.